These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 9345404

  • 1. Treatment of relapsing-remitting multiple sclerosis with natural interferon beta: a multicenter, randomized clinical trial.
    Fernández O, Antiquëdad A, Arbizu T, Capdevíla A, de Castro P, Correa de Sa JC, García-Merino JA, Izquierdo G, Magalhaes A, Montalbán X.
    Mult Scler; 1995; 1 Suppl 1():S67-9. PubMed ID: 9345404
    [Abstract] [Full Text] [Related]

  • 2. [Natural interferon-beta in the treatment of relapsing-remitting multiple sclerosis: a multicenter, randomized, MRI-based, phase II clinical trial].
    Fernández O, Antigüedad A, Arbizu T, Burgués S, Capdevila A, de Castro P, Correa de Sá JC, García-Merino JA, Izquierdo G, Magalhaes A, Montalbán X, Zarranz JJ.
    Rev Neurol; 1995; 29(12):1093-9. PubMed ID: 10652728
    [Abstract] [Full Text] [Related]

  • 3. Human recombinant interferon beta in the treatment of relapsing-remitting multiple sclerosis: preliminary observations.
    Fieschi C, Pozzilli C, Bastianello S, Koudriavtseva T, Gasperini C, Bozzao A, Galgani S, Paolillo A, Millefiorini E, Buttinelli C.
    Mult Scler; 1995; 1 Suppl 1():S28-31. PubMed ID: 9345395
    [Abstract] [Full Text] [Related]

  • 4. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR, Panitch HS.
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [Abstract] [Full Text] [Related]

  • 5. Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis.
    Sandberg-Wollheim M, Hommes OR, Hughes RA, Paty DW, Abdul-Ahad AK.
    Mult Scler; 1995 Sep; 1 Suppl 1():S48-50. PubMed ID: 9345399
    [Abstract] [Full Text] [Related]

  • 6. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 7. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis.
    Cocco E, Marchi P, Floris G, Mascia MG, Deriu M, Sirca A, Mamusa E, Lai M, Mura M, Mallarini G, Marrosu MG.
    Funct Neurol; 2006 Jun; 21(3):145-9. PubMed ID: 17049133
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD.
    Neurology; 2009 Jun 09; 72(23):1976-83. PubMed ID: 19279320
    [Abstract] [Full Text] [Related]

  • 9. Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial.
    Polman CH, Dahlke F, Thompson AJ, Ghazi M, Kappos L, Miltenburger C, Pozilli C.
    Mult Scler; 1995 Jun 09; 1 Suppl 1():S51-4. PubMed ID: 9345400
    [Abstract] [Full Text] [Related]

  • 10. Early treatment of multiple sclerosis with Rebif (recombinant human interferon beta): design of the study.
    Comi G, Barkhof F, Durelli L, Edan G, Fernandez O, Filippi M, Hartung HP, Hommes OR, Seeldrayers P, Soelberg-Sorensen P.
    Mult Scler; 1995 Jun 09; 1 Suppl 1():S24-7. PubMed ID: 9345394
    [Abstract] [Full Text] [Related]

  • 11. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
    Barbero P, Verdun E, Bergui M, Pipieri A, Clerico M, Cucci A, Ricci A, Bergamasco B, Durelli L.
    J Neurol Sci; 2004 Jul 15; 222(1-2):13-9. PubMed ID: 15240190
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.
    Arch Neurol; 2008 Feb 15; 65(2):199-204. PubMed ID: 18071030
    [Abstract] [Full Text] [Related]

  • 14. Magnetic resonance imaging as an outcome measure in the treatment of multiple sclerosis: results of the interferon beta trial.
    Koopmans RA, Paty DW.
    Mult Scler; 1995 Feb 15; 1 Suppl 1():S22-3. PubMed ID: 9345393
    [No Abstract] [Full Text] [Related]

  • 15. Interferon alpha treatment of relapsing-remitting multiple sclerosis: long-term study of the correlations between clinical and magnetic resonance imaging results and effects on the immune function.
    Durelli L, Bongioanni MR, Cavallo R, Ferrero B, Ferri R, Verdun E, Bradac GB, Riva A, Geuna M, Bergamini L.
    Mult Scler; 1995 Feb 15; 1 Suppl 1():S32-7. PubMed ID: 9345396
    [Abstract] [Full Text] [Related]

  • 16. Early treatment trials with interferon beta in multiple sclerosis.
    Panitch HS.
    Mult Scler; 1995 Feb 15; 1 Suppl 1():S17-21. PubMed ID: 9345392
    [Abstract] [Full Text] [Related]

  • 17. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
    Neurology; 1995 Jul 15; 45(7):1277-85. PubMed ID: 7617182
    [Abstract] [Full Text] [Related]

  • 18. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
    Saida T, Tashiro K, Itoyama Y, Sato T, Ohashi Y, Zhao Z, Interferon Beta-1b Multiple Sclerosis Study Group of Japan.
    Neurology; 2005 Feb 22; 64(4):621-30. PubMed ID: 15728282
    [Abstract] [Full Text] [Related]

  • 19. Disease-modifying therapy in relapsing--remitting multiple sclerosis: efficacy is paramount.
    Cristiano E.
    Int J Clin Pract Suppl; 2002 Sep 22; (131):3-7. PubMed ID: 12564806
    [Abstract] [Full Text] [Related]

  • 20. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
    Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, Panitch H, Goodin D, Li D, Chang P, Francis G, EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study Group, University of British Columbia MS/MRI Research Group.
    Arch Neurol; 2005 May 22; 62(5):785-92. PubMed ID: 15883267
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.